{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:28:57Z","timestamp":1793384937966,"version":"4.5.0"},"reference-count":113,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>:<\/jats:title>\n                    <jats:p>Motor neuron disorders encompass a spectrum of conditions that can be inherited or\narise from spontaneous gene mutations. These disorders disrupt the crucial connection between\nmotor neurons and muscles, leading to a range of symptoms, including muscle weakness, impaired\ncoordination, and abnormal movements. Unfortunately, despite the significant impact on\nindividuals' quality of life, there is currently no definitive cure for these disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>:<\/jats:title>\n                    <jats:p>In response to this pressing medical need, extensive research efforts are underway globally to\ndevelop effective treatments for motor neuron disorders. Among the emerging therapeutic strategies,\ngene therapy has shown considerable promise. By targeting the underlying genetic abnormalities\nresponsible for these disorders, gene therapy aims to correct or mitigate the dysfunctional\nmolecular pathways, offering hope for improved outcomes and potentially even disease reversal.\nVarious approaches are being explored within the realm of gene therapy, with genetic modification\ntechniques taking center stage. These techniques enable precise manipulation of the\ngenetic material, facilitating the replacement of mutated genes with functional ones. One such\ntechnique that has garnered attention for its potential therapeutic efficacy is Zinc Finger Nucleases\n(ZFNs). ZFNs are molecular tools designed to target specific DNA sequences with high\nprecision, enabling targeted gene editing. Their ability to induce targeted modifications in the\ngenome holds significant promise for treating motor neuron disorders by correcting diseasecausing\nmutations. Moreover, ZFNs offer advantages such as accuracy and desirable therapeutic\neffects, making them an attractive option for gene therapy applications. Despite their potential, it\nis essential to acknowledge the limitations and challenges associated with ZFN-based gene therapy.\nThese include off-target effects, delivery methods, and immune responses. Understanding\nand addressing these challenges are critical steps toward realizing the full therapeutic potential of\nZFNs in treating motor neuron disorders. In this comprehensive review, we delve into the intricacies\nof ZFNs, exploring their mechanisms of action, current applications, limitations, and future\nprospects in gene therapy for motor neuron disorders. Additionally, we provide insights into\nother nucleases-mediated gene therapy approaches, highlighting their comparative advantages\nand challenges. Furthermore, we discuss factors influencing the efficacy and safety of gene therapy\ntreatments, including delivery methods, immune responses, and ethical considerations. By\nexamining these factors in detail, we aim to provide a holistic understanding of the complex\nlandscape of gene therapy for motor neuron disorders and pave the way for future advancements\nin the field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113892010307288240526071810","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T05:58:26Z","timestamp":1717739906000},"page":"1514-1531","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Genome Editing Approaches Using Zinc Finger Nucleases (ZFNs) for the Treatment of Motor Neuron Diseases"],"prefix":"10.2174","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5707-7289","authenticated-orcid":true,"given":"Medisetti","family":"Manikishore","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar (M.P.)\n470003, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0856-5730","authenticated-orcid":true,"given":"Sandeep Kumar","family":"Maurya","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar (M.P.)\n470003, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-5982","authenticated-orcid":true,"given":"Sunny","family":"Rathee","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar (M.P.)\n470003, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2096-9922","authenticated-orcid":true,"given":"Umesh Kumar","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar (M.P.)\n470003, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1212\/01.CON.0000455886.14298.a4","volume":"20","author":"Tiryaki E.","year":"2014","unstructured":"Tiryaki E.; Horak H.A.; ALS and other motor neuron diseases. Continuum (Minneap Minn)  2014,20(5 Peripheral Nervous System Disorders),1185-1207","journal-title":"Continuum (Minneap Minn)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1136\/jnnp.2009.188151","volume":"9","author":"Talbot K.","year":"2009","unstructured":"Talbot K.; Motor neuron disease: The bare essentials. Pract Neurol  2009,9(5),303-309","journal-title":"Pract Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3389\/fneur.2019.00291","volume":"10","author":"Verber N.S.","year":"2019","unstructured":"Verber N.S.; Shepheard S.R.; Sassani M.; McDonough H.E.; Moore S.A.; Alix J.J.P.; Wilkinson I.D.; Jenkins T.M.; Shaw P.J.; Biomarkers in motor neuron disease: A state of the art review. Front Neurol  2019,10,291","journal-title":"Front Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ymthe.2021.04.003","volume":"30","author":"Miccio A.","year":"2022","unstructured":"Miccio A.; Antoniou P.; Ciura S.; Kabashi E.; Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges. Mol Ther  2022,30(1),47-53","journal-title":"Mol Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrg2842","volume":"11","author":"Urnov F.D.","year":"2010","unstructured":"Urnov F.D.; Rebar E.J.; Holmes M.C.; Zhang H.S.; Gregory P.D.; Genome editing with engineered zinc finger nucleases. Nat Rev Genet  2010,11(9),636-646","journal-title":"Nat Rev Genet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/pmj.78.923.513","volume":"78","author":"Talbot K.","year":"2002","unstructured":"Talbot K.; Motor neurone disease. Postgrad Med J  2002,78(923),513-519","journal-title":"Postgrad Med J"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.5694\/mja16.01063","volume":"206","author":"Dharmadasa T.","year":"2017","unstructured":"Dharmadasa T.; Henderson R.D.; Talman P.S.; Macdonell R.A.L.; Mathers S.; Schultz D.W.; Needham M.; Zoing M.; Vucic S.; Kiernan M.C.; Motor neurone disease: Progress and challenges. Med J Aust  2017,206(8),357-362","journal-title":"Med J Aust"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","volume":"400","author":"Feldman E.L.","year":"2022","unstructured":"Feldman E.L.; Goutman S.A.; Petri S.; Mazzini L.; Savelieff M.G.; Shaw P.J.; Sobue G.; Amyotrophic lateral sclerosis. Lancet  2022,400(10360),1363-1380","journal-title":"Lancet"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"Brown R.H.","year":"2017","unstructured":"Brown R.H.; Al-Chalabi A.; Amyotrophic lateral sclerosis. N Engl J Med  2017,377(2),162-172","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrneurol.2011.153","volume":"7","author":"Hardiman O.","year":"2011","unstructured":"Hardiman O.; van den Berg L.H.; Kiernan M.C.; Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol  2011,7(11),639-649","journal-title":"Nat Rev Neurol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3109\/17482960903513159","volume":"11","author":"Karam C.","year":"2010","unstructured":"Karam C.; Scelsa S.N.; MacGowan D.J.L.; The clinical course of progressive bulbar palsy. Amyotroph Lateral Scler  2010,11(4),364-368","journal-title":"Amyotroph Lateral Scler"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.4103\/0366-6999.211538","volume":"130","author":"Zhang H.G.","year":"2017","unstructured":"Zhang H.G.; Chen L.; Tang L.; Zhang N.; Fan D.S.; Clinical features of isolated bulbar palsy of amyotrophic lateral sclerosis in Chinese population. Chin Med J (Engl)  2017,130(15),1768-1772","journal-title":"Chin Med J (Engl)"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.ncl.2015.07.007","volume":"33","author":"Statland J.M.","year":"2015","unstructured":"Statland J.M.; Barohn R.J.; Dimachkie M.M.; Floeter M.K.; Mitsumoto H.; Primary lateral sclerosis. Neurol Clin  2015,33(4),749-760","journal-title":"Neurol Clin"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/jnnp-2019-322541","volume":"91","author":"Turner M.R.","year":"2020","unstructured":"Turner M.R.; Barohn R.J.; Corcia P.; Fink J.K.; Harms M.B.; Kiernan M.C.; Ravits J.; Silani V.; Simmons Z.; Statland J.; van den Berg L.H.; Mitsumoto H.; Primary lateral sclerosis: Consensus diagnostic criteria. J Neurol Neurosurg Psychiatry  2020,91(4),373-377","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/ane.12713","volume":"136","author":"Wais V.","year":"2017","unstructured":"Wais V.; Rosenbohm A.; Petri S.; Kollewe K.; Hermann A.; Storch A.; Hanisch F.; Zierz S.; Nagel G.; Kassubek J.; Weydt P.; Brettschneider J.; Weishaupt J.H.; Ludolph A.C.; Dorst J.; The concept and diagnostic criteria of primary lateral sclerosis. Acta Neurol Scand  2017,136(3),204-211","journal-title":"Acta Neurol Scand"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ncl.2015.07.005","volume":"33","author":"Liewluck T.","year":"2015","unstructured":"Liewluck T.; Saperstein D.S.; Progressive muscular atrophy. Neurol Clin  2015,33(4),761-773","journal-title":"Neurol Clin"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1212\/WNL.0b013e3181c1dea3","volume":"73","author":"Kim W.K.","year":"2009","unstructured":"Kim W.K.; Liu X.; Sandner J.; Pasmantier M.; Andrews J.; Rowland L.P.; Mitsumoto H.; Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology  2009,73(20),1686-1692","journal-title":"Neurology"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","volume":"16","author":"Mercuri E.","year":"2020","unstructured":"Mercuri E.; Pera M.C.; Scoto M.; Finkel R.; Muntoni F.; Spinal muscular atrophy \u2014 insights and challenges in the treatment era. Nat Rev Neurol  2020,16(12),706-715","journal-title":"Nat Rev Neurol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"Lunn M.R.","year":"2008","unstructured":"Lunn M.R.; Wang C.H.; Spinal muscular atrophy. Lancet  2008,371(9630),2120-2133","journal-title":"Lancet"},{"key":"ref=20","first-page":"1993","author":"Prior T.W.","year":"1993","unstructured":"Prior T.W.; Leach M.E.; Finanger E.;  Spinal muscular atrophy  1993,1993-2024","journal-title":"Spinal muscular atrophy"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00415-018-8968-7","volume":"266","author":"Breza M.","year":"2019","unstructured":"Breza M.; Koutsis G.; Kennedy\u2019s disease (spinal and bulbar muscular atrophy): A clinically oriented review of a rare disease. J Neurol  2019,266(3),565-573","journal-title":"J Neurol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s13311-019-00790-9","volume":"16","author":"Arnold F.J.","year":"2019","unstructured":"Arnold F.J.; Merry D.E.; Molecular mechanisms and therapeutics for SBMA\/Kennedy\u2019s disease. Neurotherapeutics  2019,16(4),928-947","journal-title":"Neurotherapeutics"},{"key":"ref=23","first-page":"7412","volume":"13","author":"Chen J.","year":"2021","unstructured":"Chen J.; Long X.; Han Y.; Using genetic testing to diagnose Kennedy\u2019s disease: A case report and literature review. Am J Transl Res  2021,13(6),7412-7417","journal-title":"Am J Transl Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4103\/ijabmr.IJABMR_333_18","volume":"9","author":"Olunu E.","year":"2019","unstructured":"Olunu E.; Fakoya A.O.; Oluwasanmi O.J.; Mckenzie D.A.; Adewole I.O.; Aluka C.O.; Iyasse J.; Postpolio syndrome: A review of lived experiences of patients. Int J Appl Basic Med Res  2019,9(3),129-134","journal-title":"Int J Appl Basic Med Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11940-004-0018-3","volume":"6","author":"Jubelt B.","year":"2004","unstructured":"Jubelt B.; Post-polio syndrome. Curr Treat Options Neurol  2004,6(2),87-93","journal-title":"Curr Treat Options Neurol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1468-1331.2006.01385.x","volume":"13","author":"Farbu E.","year":"2006","unstructured":"Farbu E.; Gilhus N.E.; Barnes M.P.; Borg K.; De Visser M.; Driessen A.; Howard R.; Nollet F.; Opara J.; Stalberg E.; EFNS guideline on diagnosis and management of post\u2010polio syndrome. Report of an EFNS task force. Eur J Neurol  2006,13(8),795-801","journal-title":"Eur J Neurol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s43141-020-00078-y","volume":"18","author":"Khalil A.M.","year":"2020","unstructured":"Khalil A.M.; The genome editing revolution: Review. J Genet Eng Biotechnol  2020,18(1),68","journal-title":"J Genet Eng Biotechnol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","volume":"578","author":"Doudna J.A.","year":"2020","unstructured":"Doudna J.A.; The promise and challenge of therapeutic genome editing. Nature  2020,578(7794),229-236","journal-title":"Nature"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"a023754","DOI":"10.1101\/cshperspect.a023754","volume":"8","author":"Gaj T.","year":"2016","unstructured":"Gaj T.; Sirk S.J.; Shui S.; Liu J.; Genome-editing technologies: Principles and applications. Cold Spring Harb Perspect Biol  2016,8(12),a023754","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.xcrm.2021.100346","volume":"2","author":"Chaytow H.","year":"2021","unstructured":"Chaytow H.; Faller K.M.E.; Huang Y.T.; Gillingwater T.H.; Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med  2021,2(7),100346","journal-title":"Cell Rep Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.18553\/jmcp.2018.24.12-a.s3","volume":"24","author":"Rao VK","year":"2018","unstructured":"Rao VK; Kapp D; Schroth M; Gene therapy for spinal muscular atrophy: An emerging treatment option for a devastating disease. J Manag Care Spec Pharm  2018,24(12-a Suppl),S3-S16","journal-title":"J Manag Care Spec Pharm"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"107719","DOI":"10.1016\/j.pharmthera.2020.107719","volume":"220","author":"Iftikhar M.","year":"2021","unstructured":"Iftikhar M.; Frey J.; Shohan M.J.; Malek S.; Mousa S.A.; Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy. Pharmacol Ther  2021,220,107719","journal-title":"Pharmacol Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.3390\/jcm9072222","volume":"9","author":"Messina S.","year":"2020","unstructured":"Messina S.; Sframeli M.; New treatments in spinal muscular atrophy: Positive results and new challenges. J Clin Med  2020,9(7),2222","journal-title":"J Clin Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1007\/s00018-020-03492-0","volume":"77","author":"Perego M.G.L.","year":"2020","unstructured":"Perego M.G.L.; Galli N.; Nizzardo M.; Govoni A.; Taiana M.; Bresolin N.; Comi G.P.; Corti S.; Current understanding of and emerging treatment options for spinal muscular atrophy with respiratory distress type 1 (SMARD1). Cell Mol Life Sci  2020,77(17),3351-3367","journal-title":"Cell Mol Life Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/ph14060565","volume":"14","author":"Karpe Y.","year":"2021","unstructured":"Karpe Y.; Chen Z.; Li X.J.; Stem cell models and gene targeting for human motor neuron diseases. Pharmaceuticals  2021,14(6),565","journal-title":"Pharmaceuticals"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12929-023-00943-1","volume":"30","author":"Mikkelsen N.S.","year":"2023","unstructured":"Mikkelsen N.S.; Bak R.O.; Enrichment strategies to enhance genome editing. J Biomed Sci  2023,30(1),51","journal-title":"J Biomed Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1126\/science.1079512","volume":"300","author":"Bibikova M.","year":"2003","unstructured":"Bibikova M.; Beumer K.; Trautman J.K.; Carroll D.; Enhancing gene targeting with designed zinc finger nucleases. Science  2003,300(5620),764","journal-title":"Science"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.bbrc.2005.07.089","volume":"335","author":"Mani M.","year":"2005","unstructured":"Mani M.; Kandavelou K.; Dy F.J.; Durai S.; Chandrasegaran S.; Design, engineering, and characterization of zinc finger nucleases. Biochem Biophys Res Commun  2005,335(2),447-457","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1534\/genetics.111.131433","volume":"188","author":"Carroll D.","year":"2011","unstructured":"Carroll D.; Genome engineering with zinc-finger nucleases. Genetics  2011,188(4),773-782","journal-title":"Genetics"},{"key":"ref=40","author":"Marintcheva B.","year":"2017","unstructured":"Marintcheva B.;  Harnessing the power of viruses  2017","journal-title":"Harnessing the power of viruses"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/archdischild-2016-310459","volume":"101","author":"Redman M.","year":"2016","unstructured":"Redman M.; King A.; Watson C.; King D.; What is CRISPR\/Cas9? Arch Dis Child Educ Pract Ed  2016,101(4),213-215","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0339-7","volume":"51","author":"Moon S.B.","year":"2019","unstructured":"Moon S.B.; Kim D.Y.; Ko J.H.; Kim Y.S.; Recent advances in the CRISPR genome editing tool set. Exp Mol Med  2019,51(11),1-11","journal-title":"Exp Mol Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.32607\/20758251-2014-6-3-19-40","volume":"6","author":"Nemudryi A.A.","year":"2014","unstructured":"Nemudryi A.A.; Valetdinova K.R.; Medvedev S.P.; Zakian S.M.; TALEN and CRISPR\/Cas genome editing systems: Tools of discovery. Acta Nat (Engl Ed)  2014,6(3),19-40","journal-title":"Acta Nat (Engl Ed)"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.sjbs.2021.11.037","volume":"29","author":"Raza S.H.A.","year":"2022","unstructured":"Raza S.H.A.; Hassanin A.A.; Pant S.D.; Bing S.; Sitohy M.Z.; Abdelnour S.A.; Alotaibi M.A.; Al-Hazani T.M.; Abd El-Aziz A.H.; Cheng G.; Zan L.; Potentials, prospects and applications of genome editing technologies in livestock production. Saudi J Biol Sci  2022,29(4),1928-1935","journal-title":"Saudi J Biol Sci"},{"key":"ref=45","first-page":"75","volume":"15","author":"Bordbar M.","year":"2020","unstructured":"Bordbar M.; Darvishzadeh R.; Pazhouhandeh M.; Kahrizi D.; An overview of genome editing methods based on endonucleases. Scientific Quarterly Journal of Modern Genetics  2020,15(2),75-92","journal-title":"Scientific Quarterly Journal of Modern Genetics"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1517\/14712590903213669","volume":"9","author":"Galetto R.","year":"2009","unstructured":"Galetto R.; Duchateau P.; P\u00e2ques F.; Targeted approaches for gene therapy and the emergence of engineered meganucleases. Expert Opin Biol Ther  2009,9(10),1289-1303","journal-title":"Expert Opin Biol Ther"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.omtn.2019.02.027","volume":"16","author":"Khan S.H.","year":"2019","unstructured":"Khan S.H.; Genome-editing technologies: Concept, pros, and cons of various genome-editing techniques and bioethical concerns for clinical application. Mol Ther Nucleic Acids  2019,16,326-334","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1741-7015-8-42","volume":"8","author":"Davis D.","year":"2010","unstructured":"Davis D.; Stokoe D.; Zinc Finger Nucleases as tools to understand and treat human diseases. BMC Med  2010,8(1),42","journal-title":"BMC Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2174\/156652311794520120","volume":"11","author":"H\u00e4ndel E.M.","year":"2011","unstructured":"H\u00e4ndel E.M.; Cathomen T.; Zinc-finger nuclease based genome surgery: It\u2019s all about specificity. Curr Gene Ther  2011,11(1),28-37","journal-title":"Curr Gene Ther"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jconrel.2014.12.036","volume":"205","author":"Ain Q.U.","year":"2015","unstructured":"Ain Q.U.; Chung J.Y.; Kim Y.H.; Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN. J Control Release  2015,205,120-127","journal-title":"J Control Release"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40364-021-00345-1","volume":"10","author":"Li X.","year":"2022","unstructured":"Li X.; Han M.; Zhang H.; Liu F.; Pan Y.; Zhu J.; Liao Z.; Chen X.; Zhang B.; Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma. Biomark Res  2022,10(1),2","journal-title":"Biomark Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033583510000089","volume":"43","author":"Klug A.","year":"2010","unstructured":"Klug A.; The discovery of zinc fingers and their development for practical applications in gene regulation and genome manipulation. Q Rev Biophys  2010,43(1),1-21","journal-title":"Q Rev Biophys"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1042\/BST0390584","volume":"39","author":"Halford S.E.","year":"2011","unstructured":"Halford S.E.; Catto L.E.; Pernstich C.; Rusling D.A.; Sanders K.L.; The reaction mechanism of FokI excludes the possibility of targeting zinc finger nucleases to unique DNA sites. Biochem Soc Trans  2011,39(2),584-588","journal-title":"Biochem Soc Trans"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"S305","DOI":"10.1016\/j.ymthe.2006.08.875","volume":"13","author":"Miller J.C.","year":"2006","unstructured":"Miller J.C.; Holmes M.; Wang J.; Lee Y.L.; Rupniewski I.; Waite A.; Guschin D.; Gregory P.; Pabo C.O.; Rebar E.J.; 787. Engineered Fok I Heterodimers for Enhanced Zinc Finger Nuclease Specificity. Mol Ther  2006,13,S305","journal-title":"Mol Ther"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1016\/j.ymthe.2022.10.010","volume":"30","author":"Harmatz P.","year":"2022","unstructured":"Harmatz P.; Prada C.E.; Burton B.K.; Lau H.; Kessler C.M.; Cao L.; Falaleeva M.; Villegas A.G.; Zeitler J.; Meyer K.; Miller W.; Wong Po Foo C.; Vaidya S.; Swenson W.; Shiue L.H.; Rouy D.; Muenzer J.; First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I\/II and hemophilia B. Mol Ther  2022,30(12),3587-3600","journal-title":"Mol Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/mt.2008.233","volume":"17","author":"H\u00e4ndel E.M.","year":"2009","unstructured":"H\u00e4ndel E.M.; Alwin S.; Cathomen T.; Expanding or restricting the target site repertoire of zinc-finger nucleases: The inter-domain linker as a major determinant of target site selectivity. Mol Ther  2009,17(1),104-111","journal-title":"Mol Ther"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/genetics\/161.3.1169","volume":"161","author":"Bibikova M.","year":"2002","unstructured":"Bibikova M.; Golic M.; Golic K.G.; Carroll D.; Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics  2002,161(3),1169-1175","journal-title":"Genetics"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-7774-1_2","author":"Waryah CB","year":"2018","unstructured":"Waryah CB; Moses C; Arooj M; Blancafort P; Zinc fingers, TALEs, and CRISPR systems: A comparison of tools for epigenome editing. Epigenome editing: methods and protocols  2018,19-63","journal-title":"Epigenome editing: methods and protocols"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"e01911","DOI":"10.7554\/eLife.01911","volume":"3","author":"Cai Y.","year":"2014","unstructured":"Cai Y.; Bak R.O.; Mikkelsen J.G.; Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases. eLife  2014,3,e01911","journal-title":"eLife"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1093\/nar\/gkr1214","volume":"40","author":"Perez-Pinera P.","year":"2012","unstructured":"Perez-Pinera P.; Ousterout D.G.; Brown M.T.; Gersbach C.A.; Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases. Nucleic Acids Res  2012,40(8),3741-3752","journal-title":"Nucleic Acids Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ymthe.2019.01.014","volume":"27","author":"Zhang H.X.","year":"2019","unstructured":"Zhang H.X.; Zhang Y.; Yin H.; Genome editing with mRNA encoding ZFN, TALEN, and Cas9. Mol Ther  2019,27(4),735-746","journal-title":"Mol Ther"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1073\/pnas.93.3.1156","volume":"93","author":"Kim Y.G.","year":"1996","unstructured":"Kim Y.G.; Cha J.; Chandrasegaran S.; Hybrid restriction enzymes: Zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA  1996,93(3),1156-1160","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1146\/annurev-biochem-060713-035418","volume":"83","author":"Carroll D.","year":"2014","unstructured":"Carroll D.; Genome engineering with targetable nucleases. Annu Rev Biochem  2014,83(1),409-439","journal-title":"Annu Rev Biochem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3390\/cells9071608","volume":"9","author":"Naeem M.","year":"2020","unstructured":"Naeem M.; Majeed S.; Hoque M.Z.; Ahmad I.; Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing. Cells  2020,9(7),1608","journal-title":"Cells"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/ijms24021130","volume":"24","author":"Lejman J.","year":"2023","unstructured":"Lejman J.; Panuciak K.; Nowicka E.; Mastalerczyk A.; Wojciechowska K.; Lejman M.; Gene therapy in ALS and SMA: Advances, challenges and perspectives. Int J Mol Sci  2023,24(2),1130","journal-title":"Int J Mol Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/glia.22903","volume":"64","author":"Zhang P.W.","year":"2016","unstructured":"Zhang P.W.; Haidet-Phillips A.M.; Pham J.T.; Lee Y.; Huo Y.; Tienari P.J.; Maragakis N.J.; Sattler R.; Rothstein J.D.; Generation of GFAP:GFP astrocyte reporter lines from human adult fibroblast\u2010derived i PS cells using zinc\u2010finger nuclease technology. Glia  2016,64(1),63-75","journal-title":"Glia"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd.2016.280","volume":"16","author":"Yin H.","year":"2017","unstructured":"Yin H.; Kauffman K.J.; Anderson D.G.; Delivery technologies for genome editing. Nat Rev Drug Discov  2017,16(6),387-399","journal-title":"Nat Rev Drug Discov"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3390\/ijms17050626","volume":"17","author":"Wang L.","year":"2016","unstructured":"Wang L.; Li F.; Dang L.; Liang C.; Wang C.; He B.; Liu J.; Li D.; Wu X.; Xu X.; Lu A.; Zhang G.; In vivo delivery systems for therapeutic genome editing. Int J Mol Sci  2016,17(5),626","journal-title":"Int J Mol Sci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/2277-9175.98152","volume":"1","author":"Nayerossadat N.","year":"2012","unstructured":"Nayerossadat N.; Maedeh T.; Ali P.; Viral and nonviral delivery systems for gene delivery. Adv Biomed Res  2012,1(1),27","journal-title":"Adv Biomed Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41434-019-0119-y","volume":"27","author":"Maggio I.","year":"2020","unstructured":"Maggio I.; Zittersteijn H.A.; Wang Q.; Liu J.; Janssen J.M.; Ojeda I.T.; van der Maarel S.M.; Lankester A.C.; Hoeben R.C.; Gon\u00e7alves M.A.F.V.; Integrating gene delivery and gene-editing technologies by adenoviral vector transfer of optimized CRISPR-Cas9 components. Gene Ther  2020,27(5),209-225","journal-title":"Gene Ther"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s13534-021-00199-4","volume":"11","author":"Sioson V.A.","year":"2021","unstructured":"Sioson V.A.; Kim M.; Joo J.; Challenges in delivery systems for CRISPR-based genome editing and opportunities of nanomedicine. Biomed Eng Lett  2021,11(3),217-233","journal-title":"Biomed Eng Lett"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1021\/acs.accounts.9b00106","volume":"52","author":"Wilbie D.","year":"2019","unstructured":"Wilbie D.; Walther J.; Mastrobattista E.; Delivery aspects of CRISPR\/Cas for in vivo genome editing. Acc Chem Res  2019,52(6),1555-1564","journal-title":"Acc Chem Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40824-019-0156-z","volume":"23","author":"Sung Y.K.","year":"2019","unstructured":"Sung Y.K.; Kim S.W.; Recent advances in the development of gene delivery systems. Biomater Res  2019,23(1),8","journal-title":"Biomater Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3390\/ijms24032298","volume":"24","author":"Brooks I.R.","year":"2023","unstructured":"Brooks I.R.; Sheriff A.; Moran D.; Wang J.; Jack\u00f3w J.; Challenges of gene editing therapies for genodermatoses. Int J Mol Sci  2023,24(3),2298","journal-title":"Int J Mol Sci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/pcmedi\/pbab014","volume":"4","author":"Liu W.","year":"2021","unstructured":"Liu W.; Li L.; Jiang J.; Wu M.; Lin P.; Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precis Clin Med  2021,4(3),179-191","journal-title":"Precis Clin Med"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"570672","DOI":"10.3389\/fimmu.2020.570672","volume":"11","author":"Pavlovic K.","year":"2020","unstructured":"Pavlovic K.; Trist\u00e1n-Manzano M.; Maldonado-P\u00e9rez N.; Cortijo-Gutierrez M.; S\u00e1nchez-Hern\u00e1ndez S.; Justicia-Lirio P.; Carmona M.D.; Herrera C.; Martin F.; Benabdellah K.; Using gene editing approaches to fine-tune the immune system. Front Immunol  2020,11,570672","journal-title":"Front Immunol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"8","DOI":"10.15388\/Amed.2021.28.2.8","volume":"28","author":"Petraityt\u0117 G.","year":"2021","unstructured":"Petraityt\u0117 G.; Preik\u0161aitien\u0117 E.; Mik\u0161tien\u0117 V.; Genome editing in medicine: Tools and challenges. Acta Med Litu  2021,28(2),8","journal-title":"Acta Med Litu"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2174\/138955708784567458","volume":"8","author":"Camenisch T.","year":"2008","unstructured":"Camenisch T.; Brilliant M.; Segal D.; Critical parameters for genome editing using zinc finger nucleases. Mini Rev Med Chem  2008,8(7),669-676","journal-title":"Mini Rev Med Chem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"Li H.","year":"2020","unstructured":"Li H.; Yang Y.; Hong W.; Huang M.; Wu M.; Zhao X.; Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects. Signal Transduct Target Ther  2020,5(1),1","journal-title":"Signal Transduct Target Ther"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1202388","DOI":"10.3389\/fbioe.2023.1202388","volume":"11","author":"Huttanus H.M.","year":"2023","unstructured":"Huttanus H.M.; Triola E.K.H.; Velasquez-Guzman J.C.; Shin S.M.; Granja-Travez R.S.; Singh A.; Dale T.; Jha R.K.; Targeted mutagenesis and high-throughput screening of diversified gene and promoter libraries for isolating gain-of-function mutations. Front Bioeng Biotechnol  2023,11,1202388","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3109\/10409238.2012.658112","volume":"47","author":"Humbert O.","year":"2012","unstructured":"Humbert O.; Davis L.; Maizels N.; Targeted gene therapies: Tools, applications, optimization. Crit Rev Biochem Mol Biol  2012,47(3),264-281","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nbt.3513","volume":"34","author":"De Ravin S.S.","year":"2016","unstructured":"De Ravin S.S.; Reik A.; Liu P.Q.; Li L.; Wu X.; Su L.; Raley C.; Theobald N.; Choi U.; Song A.H.; Chan A.; Pearl J.R.; Paschon D.E.; Lee J.; Newcombe H.; Koontz S.; Sweeney C.; Shivak D.A.; Zarember K.A.; Peshwa M.V.; Gregory P.D.; Urnov F.D.; Malech H.L.; Targeted gene addition in human CD34+ hematopoietic cells for correction of X-linked chronic granulomatous disease. Nat Biotechnol  2016,34(4),424-429","journal-title":"Nat Biotechnol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"e1000376","DOI":"10.1371\/journal.pgen.1000376","volume":"5","author":"Pruett-Miller S.M.","year":"2009","unstructured":"Pruett-Miller S.M.; Reading D.W.; Porter S.N.; Porteus M.H.; Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. PLoS Genet  2009,5(2),e1000376","journal-title":"PLoS Genet"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1358\/dof.2012.37.3.1779022","volume":"37","author":"Chou S.T.","year":"2012","unstructured":"Chou S.T.; Leng Q.; Mixson J.; Zinc finger nucleases: Tailor-made for gene therapy. Drugs Future  2012,37(3),183-196","journal-title":"Drugs Future"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/sj.mt.6300357","volume":"16","author":"Cornu T.I.","year":"2008","unstructured":"Cornu T.I.; Thibodeau-Beganny S.; Guhl E.; Alwin S.; Eichtinger M.; Joung J.K.; Cathomen T.; DNA-binding specificity is a major determinant of the activity and toxicity of zinc-finger nucleases. Mol Ther  2008,16(2),352-358","journal-title":"Mol Ther"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1182\/blood-2016-01-678136","volume":"127","author":"Kohn D.B.","year":"2016","unstructured":"Kohn D.B.; Porteus M.H.; Scharenberg A.M.; Ethical and regulatory aspects of genome editing. Blood  2016,127(21),2553-2560","journal-title":"Blood"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.tibtech.2014.12.001","volume":"33","author":"Hendel A.","year":"2015","unstructured":"Hendel A.; Fine E.J.; Bao G.; Porteus M.H.; Quantifying on- and off-target genome editing. Trends Biotechnol  2015,33(2),132-140","journal-title":"Trends Biotechnol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.3390\/ijms20153719","volume":"20","author":"Hajiahmadi Z.","year":"2019","unstructured":"Hajiahmadi Z.; Movahedi A.; Wei H.; Li D.; Orooji Y.; Ruan H.; Zhuge Q.; Strategies to increase on-target and reduce off-target effects of the CRISPR\/Cas9 system in plants. Int J Mol Sci  2019,20(15),3719","journal-title":"Int J Mol Sci"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt1319","volume":"25","author":"Miller J.C.","year":"2007","unstructured":"Miller J.C.; Holmes M.C.; Wang J.; Guschin D.Y.; Lee Y.L.; Rupniewski I.; Beausejour C.M.; Waite A.J.; Wang N.S.; Kim K.A.; Gregory P.D.; Pabo C.O.; Rebar E.J.; An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol  2007,25(7),778-785","journal-title":"Nat Biotechnol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nbt1125","volume":"23","author":"Porteus M.H.","year":"2005","unstructured":"Porteus M.H.; Carroll D.; Gene targeting using zinc finger nucleases. Nat Biotechnol  2005,23(8),967-973","journal-title":"Nat Biotechnol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1339189","DOI":"10.3389\/fbioe.2023.1339189","volume":"11","author":"Lopes R.","year":"2024","unstructured":"Lopes R.; Prasad M.K.; Beyond the promise: Evaluating and mitigating off-target effects in CRISPR gene editing for safer therapeutics. Front Bioeng Biotechnol  2024,11,1339189","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.plaphy.2018.03.027","volume":"131","author":"Kadam U.S.","year":"2018","unstructured":"Kadam U.S.; Shelake R.M.; Chavhan R.L.; Suprasanna P.; Concerns regarding \u2018off-target\u2019 activity of genome editing endonucleases. Plant Physiol Biochem  2018,131,22-30","journal-title":"Plant Physiol Biochem"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nmeth.1670","volume":"8","author":"Pattanayak V.","year":"2011","unstructured":"Pattanayak V.; Ramirez C.L.; Joung J.K.; Liu D.R.; Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods  2011,8(9),765-770","journal-title":"Nat Methods"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/B978-0-323-85679-9.00038-6","volume":"26","author":"Kovalchuk I.","year":"2021","unstructured":"Kovalchuk I.; Off-target effects in genome editing. Genome Stability  2021,26,715-727","journal-title":"Genome Stability"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1186\/s40169-020-0268-z","volume":"9","author":"Ashmore-Harris C.","year":"2020","unstructured":"Ashmore-Harris C.; Fruhwirth G.O.; The clinical potential of gene editing as a tool to engineer cell\u2010based therapeutics. Clin Transl Med  2020,9(1),e15","journal-title":"Clin Transl Med"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-genom-111320-091930","volume":"22","author":"Marchant G.E.","year":"2021","unstructured":"Marchant G.E.; Global governance of human genome editing: What are the rules? Annu Rev Genomics Hum Genet  2021,22(1),385-405","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1111\/pbi.12941","volume":"16","author":"Ran Y.","year":"2018","unstructured":"Ran Y.; Patron N.; Kay P.; Wong D.; Buchanan M.; Cao Y.Y.; Sawbridge T.; Davies J.P.; Mason J.; Webb S.R.; Spangenberg G.; Ainley W.M.; Walsh T.A.; Hayden M.J.; Zinc finger nuclease\u2010mediated precision genome editing of an endogenous gene in hexaploid bread wheat (Triticum aestivum) using a DNA repair template. Plant Biotechnol J  2018,16(12),2088-2101","journal-title":"Plant Biotechnol J"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nmeth.2143","volume":"9","author":"Straimer J.","year":"2012","unstructured":"Straimer J.; Lee M.C.S.; Lee A.H.; Zeitler B.; Williams A.E.; Pearl J.R.; Zhang L.; Rebar E.J.; Gregory P.D.; Llin\u00e1s M.; Urnov F.D.; Fidock D.A.; Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases. Nat Methods  2012,9(10),993-998","journal-title":"Nat Methods"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.nbt.2013.07.001","volume":"31","author":"Pauwels K.","year":"2014","unstructured":"Pauwels K.; Podevin N.; Breyer D.; Carroll D.; Herman P.; Engineering nucleases for gene targeting: Safety and regulatory considerations. N Biotechnol  2014,31(1),18-27","journal-title":"N Biotechnol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/gt.2008.145","volume":"15","author":"Carroll D.","year":"2008","unstructured":"Carroll D.; Progress and prospects: Zinc-finger nucleases as gene therapy agents. Gene Ther  2008,15(22),1463-1468","journal-title":"Gene Ther"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1353\/asb.2016.0026","volume":"8","author":"Qiu R.","year":"2016","unstructured":"Qiu R.; Debating ethical issues in genome editing technology. Asian Bioeth Rev  2016,8(4),307-326","journal-title":"Asian Bioeth Rev"},{"key":"ref=102","first-page":"117","volume":"11","author":"Karagyaur MN","year":"2019","unstructured":"Karagyaur MN; Efimenko AYu; Makarevich PI; Vasilue PA; Akopyan ZhA; Bryzgalina E.V; Tkachuk VA.; Ethical and legal issues in the use of genome editing technologies in medicine (review). Modern technologies in medicine  2019,11(3),117-135","journal-title":"Modern technologies in medicine"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3906\/biy-1912-52","volume":"44","author":"Ayano\u011flu F.B.","year":"2020","unstructured":"Ayano\u011flu F.B.; El\u00e7i\u0307n A.E.; El\u00e7i\u0307n Y.M.; Bioethical issues in genome editing by CRISPR-Cas9 technology. Turk J Biol  2020,44(2),110-120","journal-title":"Turk J Biol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"Cox D.B.T.","year":"2015","unstructured":"Cox D.B.T.; Platt R.J.; Zhang F.; Therapeutic genome editing: Prospects and challenges. Nat Med  2015,21(2),121-131","journal-title":"Nat Med"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12910-023-00951-8","volume":"24","author":"Selin C.","year":"2023","unstructured":"Selin C.; Lambert L.; Morain S.; Nelson J.P.; Barlevy D.; Farooque M.; Manley H.; Scott C.T.; Researching the future: Scenarios to explore the future of human genome editing. BMC Med Ethics  2023,24(1),72","journal-title":"BMC Med Ethics"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/2052-8426-2-27","volume":"2","author":"Amer M.H.","year":"2014","unstructured":"Amer M.H.; Gene therapy for cancer: Present status and future perspective. Mol Cell Ther  2014,2(1),27","journal-title":"Mol Cell Ther"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jamaneurol.2016.3388","volume":"73","author":"Long C.","year":"2016","unstructured":"Long C.; Amoasii L.; Bassel-Duby R.; Olson E.N.; Genome editing of monogenic neuromuscular diseases: A systematic review. JAMA Neurol  2016,73(11),1349-1355","journal-title":"JAMA Neurol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/nar\/gkq787","volume":"39","author":"Gupta A.","year":"2011","unstructured":"Gupta A.; Meng X.; Zhu L.J.; Lawson N.D.; Wolfe S.A.; Zinc finger protein-dependent and -independent contributions to the in vivo off-target activity of zinc finger nucleases. Nucleic Acids Res  2011,39(1),381-392","journal-title":"Nucleic Acids Res"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jconrel.2016.11.014","volume":"244","author":"Liu J.","year":"2016","unstructured":"Liu J.; Shui S.; Delivery methods for site-specific nucleases: Achieving the full potential of therapeutic gene editing. J Control Release  2016,244(Pt A),83-97","journal-title":"J Control Release"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/gt.2012.2","volume":"20","author":"Palpant N.J.","year":"2013","unstructured":"Palpant N.J.; Dudzinski D.; Zinc finger nucleases: Looking toward translation. Gene Ther  2013,20(2),121-127","journal-title":"Gene Ther"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1161\/CIRCRESAHA.112.274969","volume":"111","author":"Wang Y.","year":"2012","unstructured":"Wang Y.; Zhang W.Y.; Hu S.; Lan F.; Lee A.S.; Huber B.; Lisowski L.; Liang P.; Huang M.; de Almeida P.E.; Won J.H.; Sun N.; Robbins R.C.; Kay M.A.; Urnov F.D.; Wu J.C.; Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for cellular imaging. Circ Res  2012,111(12),1494-1503","journal-title":"Circ Res"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nature03556","volume":"435","author":"Urnov F.D.","year":"2005","unstructured":"Urnov F.D.; Miller J.C.; Lee Y.L.; Beausejour C.M.; Rock J.M.; Augustus S.; Jamieson A.C.; Porteus M.H.; Gregory P.D.; Holmes M.C.; Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature  2005,435(7042),646-651","journal-title":"Nature"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1021\/ar500039w","volume":"47","author":"Gersbach C.A.","year":"2014","unstructured":"Gersbach C.A.; Gaj T.; Barbas C.F.; III Synthetic zinc finger proteins: The advent of targeted gene regulation and genome modification technologies. Acc Chem Res  2014,47(8),2309-2318","journal-title":"Acc Chem Res"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010307288240526071810","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/230797\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010307288240526071810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T04:49:24Z","timestamp":1752122964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/230797\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":113,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892010307288240526071810","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}